DOSE REDUCTION OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS WITH LOW DISEASE ACTIVITY: A PILOT STUDY

被引：0
|
作者：
van Herwaarden, N. [1 ]
Herfkens-Hol, S. [1 ]
van der Maas, A. [1 ]
van den Bemt, B. [1 ]
van Vollenhoven, R. [2 ]
Bijlsma, J. [3 ]
den Broeder, A. [1 ]
机构：
[1] Sint Maartensklin, Nijmegen, Netherlands
[2] Karolinska Inst, ClinTRID, Stockholm, Sweden
[3] Univ Med Ctr Utrecht, Utrecht, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：886 / 886
页数：1
相关论文
共 50 条
  • [1] Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity
    van Herwaarden, N.
    Herfkens-Hol, S.
    van der Maas, A.
    van den Bemt, B. J. F.
    van Vollenhoven, R. F.
    Bijlsma, J. W. J.
    den Broeder, A. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (03) : 390 - 394
  • [2] Dose Reduction Of Tocilizumab In Rheumatoid Arthritis Patients With Low Disease Activity Is Feasible
    van Herwaarden, Noortje
    Herfkens-Hol, Susan
    van der Maas, Aatke
    van Den Bemt, Bart J. F.
    van Vollenhoven, Ronald F.
    Bijlsma, Johannes W. J.
    den Broeder, Alfons A.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S992 - S992
  • [3] Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot Study
    Fechtenbaum, Marie
    Lasselin-Boyard, Pauline
    Salomon, Sarah
    Jelin, Germain
    Millot, Florence
    Grados, Franck
    Fardellone, Patrice
    Goeb, Vincent
    PHARMACOLOGY, 2016, 98 (1-2) : 73 - 78
  • [4] ETANERCEPT DOSE REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS - A PILOT STUDY IN SOUTH WALES
    Duffill, S.
    Kia, S.
    Amos, N.
    Thomas, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 500 - 500
  • [5] Dose reduction of rituximab in clinical practice: a retrospective cohort study of rheumatoid arthritis patients in low disease activity on rituximab
    Wientjes, M. H. M.
    van Huissteden, J.
    van Herwaarden, N.
    Verhoef, L. M.
    den Broeder, A. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (11) : 2215 - 2220
  • [6] GLUCOCORTICOID DOSE REDUCTION IN PATIENTS WITH LOW DISEASE ACTIVITY USING TOCILIZUMAB: THE ACT-ALONE STUDY
    Ribbens, C.
    Vanhoof, J.
    Maertens, M.
    Van Steenberghe, M.
    Verschueren, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 495 - 495
  • [7] SUSTAINABLE LOW DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: REAL-WORLD EXPERIENCE WITH TOCILIZUMAB
    Shivacheva, T.
    Georgiev, T.
    Hristova, S.
    Dimitrov, S.
    Bogdanova-Petrova, S.
    Gerganov, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1138 - 1138
  • [8] Effect of Dose Escalation of Subcutaneous Tocilizumab on Disease Activity in Patients with Rheumatoid Arthritis in a Randomized Controlled Trial
    Singer, Nora G.
    Mohan, Shalini V.
    Yourish, Jeffrey
    Han, Jian
    Edwardes, Michael
    Michalska, Margaret
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [9] EFFECT OF DOSE ESCALATION OF SUBCUTANEOUS TOCILIZUMAB ON DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A RANDOMIZED CONTROLLED TRIAL
    Singer, N.
    Mohan, S.
    Han, J.
    Edwardes, M.
    Michalska, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1126 - 1126
  • [10] Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
    Burmester, Gerd R.
    Choy, Ernest
    Kivitz, Alan
    Ogata, Atsushi
    Bao, Min
    Nomura, Akira
    Lacey, Stuart
    Pei, Jinglan
    Reiss, William
    Pethoe-Schramm, Attila
    Mallalieu, Navita L.
    Wallace, Thomas
    Michalska, Margaret
    Birnboeck, Herbert
    Stubenrauch, Kay
    Genovese, Mark C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 1078 - 1085
12345